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Abstract
Anchorage of cells to "heparin" – binding domains that are prevalent in extracellular matrix (ECM)
components is thought to occur primarily through the syndecans, a four-member family of
transmembrane heparan sulfate proteoglycans that communicate environmental cues from the
ECM to the cytoskeleton and the signaling apparatus of the cell. Known activities of the syndecans
trace to their highly conserved cytoplasmic domains and to their heparan sulfate chains, which can
serve to regulate the signaling of growth factors and morphogens. However, several emerging
studies point to critical roles for the syndecans' extracellular protein domains in tumor cell
behavior to include cell adhesion and invasion. Although the mechanisms of these activities remain
largely unknown, one possibility involves "co-receptor" interactions with integrins that may
regulate integrin function and the cell adhesion-signaling phenotype. Thus, alterations in syndecan
expression, leading to either overexpression or loss of expression, both of which take place in
tumor cells, may have dramatic effects on tumor cell invasion.
The invasive and metastatic potential of a tumor cell relies
on recognition of a variety of ECM ligands that control
proliferation, dynamic cytoskeletal remodeling, apoptosis
and gene expression. This recognition involves complex
molecular mechanisms, beginning with the expression of
specific matrix receptors, regulation of their activity, and
reception and channeling of their signals into specific
intracellular pathways. Additional complexity arises in
that matrix ligands contain multiple adhesion receptor
binding sites including sites recognized by both prote-
oglycans and integrins. In this sense, matrix ligands may
be considered as "informational arrays" that function to
modulate tumor cell phenotype by engaging specific com-
binations of cell surface adhesion receptors.
Integrins are well recognized as matrix-responsive signal-
ing receptors. Comprised of non-covalent heterodimers,
the α and β integrin subunits collaborate in "inside-out"
signaling that leads to "activation" of the receptor, classi-
cally defined as an increase in affinity for the matrix ligand
resulting from a change in conformation of the integrin
extracellular domain. However, integrins are also subject
to "outside-in" signaling in which the ligand-bound
receptor initiates intracellular signaling through associa-
tion of the β subunit cytoplasmic domain with a myriad
of intracellular effectors including focal adhesion and Src
family kinases, cytoskeletal components such as α-actinin
and vinculin and the Rho family of cytoskeletal regulatory
G-proteins. However, this may be a simplistic picture of
integrin signaling, as integrins are also known to signal in
the absence of ligand binding [1-9] and integrin activity
on cells is subject to cross-talk between heterologous
integrin receptors such that final signaling output is not a
simple additive function of all the integrins expressed on
the cell [10-15]. Thus, an alteration in the integrin
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regulatory apparatus is likely to alter the metastatic poten-
tial of a cell.
Cell surface proteoglycans (PGs) are also important in
modulating cell adhesion and motility. Many adhesion-
promoting components within the ECM – including
structural proteins (laminin, fibronectin, collagen, etc.),
growth factors, chemokines and cytokines – as well as cell
surface adhesion receptors (e.g. selectins, cell adhesion
molecules (CAMs), etc.) support cell adhesion via binding
interactions with PGs. The fact that PG binding sites exist
in close proximity to integrin cell-binding domains within
ECM molecules [16] and on other cell surface adhesion
molecules suggest that cellular recognition of the ECM, or
of counter-adhesion receptors on opposing cells, may
involve the formation of receptor complexes that include
both cell surface PGs and integrins. An implication of
such a complex model of ligand recognition is that by
concerted action PGs and integrins may alter each other's
binding affinity for ligand(s) and consequentially, modu-
late distinct but overlapping signal transduction pathways
within the cell. Accordingly, the nature of the intracellular
signals transduced by a paired integrin and cell surface PG
may be influenced by the specific integrin and/or cell sur-
face PG core proteins expressed by a cell. Interactions
between these two receptors may be direct (i.e. both
receptors form a physical complex) or indirect (i.e. func-
tional coupling – one receptor modulates the activity of
the other receptor by an intermediate molecular mecha-
nism). Understanding the nature of such physical or func-
tional receptor complexes may help to explain cell-type
specific functional differences that are often observed for
a given integrin heterodimer.
Syndecans and Cell Adhesion
The syndecans are a four-member family of transmem-
brane cell surface PGs that bear heparan sulfate gly-
cosaminoglycan (GAG) chains. The syndecans are
expressed on virtually all cell types throughout develop-
ment and adulthood, and their expression can be altered
under certain pathophysiological conditions, including
the processes of tumor onset, progression and metastasis
[17,18]. Their heparan sulfate chains endow these recep-
tors with the ability to bind numerous "heparin" – bind-
ing growth factors and morphogens, for which heparan
sulfate is an important regulator. The heparan sulfate
chains also bind to "heparin" – binding sites present in
matrix ligands, including fibronectin, vitronectin, lam-
inins and the fibrillar collagens [19]. As such, the synde-
cans are believed to have roles in cell adhesion and
signaling, possibly as co-receptors with integrins and cell-
cell adhesion molecules.
The syndecan core proteins share a high degree of conser-
vation in their short (ca. 30 amino acids) cytoplasmic
domains and transmembrane domains; in contrast, the
extracellular domains (also known as ectodomains) are
divergent with the exception of consensus sites for GAG
attachment (Figure 1). In the highly conserved cytoplas-
mic domains, a juxtamembrane C1 region is exactly con-
served (with the exception of a conservative R for K amino
acid substitution in syndecan-3) among the syndecan
across all species and has been implicated in binding pro-
tein 4.1, ezrin, radixin and moesin (FERM) domains [20-
23]. A C-terminal C2 region consisting of the amino acid
sequence EFYA is present in all syndecans and binds to
post-synaptic density 95, PSD-95; discs large, Dlg; zonula
occludens-1, ZO-1 (PDZ) domains in several proteins
including calcium/calmodulin-dependent serine protein
kinase (CASK) [24], syntenin [25], synbindin [26] and
synectin [27]. The intervening variable (V) region is dis-
tinct for each of the four family members, but its synde-
can-specific identity is conserved across species. The
function of this domain is largely unknown except in the
case of syndecan-4 (Figure 2), where it is responsible for
the assembly of syndecan-4 tetramers with PI-4,5-
bisphosphate (PIP2) and activated protein kinase C-α
(PKCα) in focal adhesions [28-34]. Overexpression of
syndecan-4 leads to enhanced focal adhesion assembly
and reduced cell motility, whereas syndecan-4 mutants
which are unable to assemble into the PIP2/PKCα rich
structures show reduced focal adhesion assembly and cell
spreading as well as reduced motility [35,36]. This assem-
bly is regulated by fibroblast growth factor (FGF) signal-
ing, which leads to serine phosphorylation of the C1
domain and failure to bind PIP2 [37,38]. The syndecan-4
C1 and V regions also bind syndesmos, a paxillin binding
protein that may serve to link syndecan-4 to the cytoskel-
eton [39]. Alpha-actinin has also been shown recently to
bind the V region of syndecan-4 [40]. As it is unlikely that
all of these interactions can occur simultaneously, one
suspects that the syndecan may take on several different
roles that change with cell activity.
Although less in known about the signaling capabilities of
the other syndecans, data are emerging. Syndecan-defi-
cient Raji lymphoblastoid cells when transfected to
express syndecan-1 acquire the ability to bind and spread
on syndecan-1 antibody or matrix ligands [41,42]. This
signaling depends on the transmembrane domain of the
PG, which is found in specialized lipid domains, as well
as a region within the syndecan-1 extracellular domain
(McQuade and Rapraeger, submitted 2003). This unique
finding suggests that the syndecan extracellular protein
domains have important functions independent of, but
most likely supplemented by, their attached GAG chains.
Transfection of syndecan-1 in COS-7 cells also stimulates
cell spreading, although the phenotype in these cells is
characterized by fascin microspike formation and mem-
brane ruffling [43]. Fascin spikes are assembled in theReproductive Biology and Endocrinology 2004, 2 http://www.rbej.com/content/2/1/3
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absence of focal contacts and their assembly is dependent
on the regulated activities of the small GTPases, Rac and
Cdc42, as well as their downstream target p21-activated
kinase (PAK) [44]. Transfection studies with various syn-
decan-1 mutants mapped the active domain required for
cell spreading to the ectodomain, although the V and C2
regions of the cytoplasmic domain are required for fascin
spike formation.
Syndecan-2, originally described as fibroglycan on fibrob-
lasts where it has been implicated in matrix assembly [45],
also has important functions in the nervous system where
it participates in the formation of dendritic spines in neu-
rons [46]. Overexpression of syndecan-2 in cultured hip-
pocampal neurons leads to precocious spine formation,
an activity that is dependent on the cytoplasmic domain
both for localization of the syndecan to the sites of spine
formation and for interaction with ephrin B2 (EphB2)
Syndecan Functional Domains Figure 1
Syndecan Functional Domains. The syndecan core proteins display a high degree of conservation across species and 
across family members within their transmembrane and cytoplasmic domains, implying that some functional redundancy may 
exist among the family members. In contrast, the ectodomains of the syndecan core proteins are highly divergent both in size 
and sequence, indicating that this domain may confer separate and unique functions to each individual family member. Specific 
functions for the ectodomain of the syndecan core proteins are almost wholly unknown.Reproductive Biology and Endocrinology 2004, 2 http://www.rbej.com/content/2/1/3
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receptors that carry out an essential phosphorylation of
the syndecan-2 [47]. In COS-1 and Swiss 3T3 cells, synde-
can-2 overexpression induces filipodial extension, which
is dependent on activation of Cdc42 [48]. Transfection
studies with deletion mutants of syndecan-2 mapped the
active domain required for filipodial extension to the
ectodomain, although the cytoplasmic domain was
required for co-distribution with F-actin – most likely via
its binding interactions with the FERM protein ezrin [23].
Intriguingly, in kidney derived epithelial LLC-PK1 cells,
ezrin has also been shown to interact with and activate
focal adhesion kinase (FAK), a scaffolding protein and
Syndecan-4 provides a mechanical link between the extracellular matrix and the actin cytoskeleton via binding interactions of  its cytoplasmic tail Figure 2
Syndecan-4 provides a mechanical link between the extracellular matrix and the actin cytoskeleton via binding 
interactions of its cytoplasmic tail. PIP2 binds to the syndecan-4 V-domain – an interaction that stabilizes syndecan-4 mul-
timers against the inner leaflet of the plasma membrane and potentiates PKCα activity. The cytoplasmic tail also interacts with 
structural and signaling proteins such as CASK, FAK, syndesmos and paxillin. Interactions with these proteins may provide 
both a mechanical and signaling link to cell surface α5β1 integrins required for focal adhesion and stress fiber formation in cells 
adherent to fibronectin. Syndecan-4 may also link directly to the actin cytoskeleton through CASK, α-actinin and the FERM 
family of actin-binding proteins. Less is understood about the functional role of the V-domains of the other syndecan family 
members. However, the low degree of conservation within this domain amongst the four syndecans suggests distinct roles for 
the cytoplasmic domains of each of the syndecans in adhesion and signaling.Reproductive Biology and Endocrinology 2004, 2 http://www.rbej.com/content/2/1/3
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cytoplasmic tyrosine kinase involved in cell adhesion,
motility and survival [49]. Moreover, interactions with the
second "heparin" – binding domain (HepII) of fibronec-
tin (type III12–14 repeats) is required for activation and sta-
bility of FAK and to maintain fibroblast cell survival [50-
52]. These results suggest that molecular interactions of
the syndecans involving organization of proteins within
specialized sub-cellular structures have functional
implications not only in regulation of cell morphology,
but also in sustaining cell survival.
Syndecan-3 (originally termed N-syndecan), which is also
found in the nervous system, has a role in binding
"heparin" – binding growth associated molecule (HB-
GAM) in the outgrowing axonal tracts of the developing
thalamocortical pathway [53,54]. Neuroblastoma cells
expressing syndecan-3 respond to HB-GAM by extending
neurites in a signaling mechanism involving Src phospho-
rylation and syndecan-3 isolated from brain extracts co-
precipitates with Src and Fyn, the Src substrate cortactin
and β-tubulin [55,56]. Syndecan-3 regulates N-methyl-D-
aspartate (NMDA) receptor-mediated long-term potentia-
tion (LTP) most likely via the activation of Src family tyro-
sine kinases, leading to enhanced LTP but impaired
hippocampal-dependent memory in syndecan-3 null
mice [57-59].
Syndecan-1 in Tumor Invasion
Syndecan-1 is highly expressed at the basolateral surface
of epithelial cells where it is thought to interact with the
actin cytoskeleton and to modulate cell adhesion and
growth factor signaling [19,60-62]. In experimental stud-
ies of malignant transformation, syndecan-1 expression is
associated with the maintenance of epithelial morphol-
ogy, anchorage-dependent growth and inhibition of inva-
siveness. Alterations in syndecan expression during
development [63] and in transformed epithelial [64,65]
are associated with an epithelial-mesenchymal transfor-
mation with attendant alterations in cell morphology,
motility, growth and differentiation. Transfection of epi-
thelial cells with anti-sense mRNA for syndecan-1 or
downregulation of syndecan-1 expression by androgen-
induced transformation results in an epithelial to mesen-
chymal transformation and increased invasion [66-68].
The loss of E-cadherin under these circumstances has long
suggested a coordinate regulation of syndecan-1 and E-
cadherin expression [63,69]. These studies, as well as oth-
ers, indicate that there appears to be a threshold require-
ment for syndecan expression to elicit its biological
activity. Syndecan-1 is downregulated in a number of epi-
thelial cancers and in pre-malignant lesions of the oral
mucosa [70] and uterine cervix [71-73], and its loss may
be an early genetic event contributing to tumor progres-
sion [17,74,75]. Loss of syndecan-1 correlates with a
reduced survival in squamous cell carcinoma of the head,
neck and lung [76-78], laryngeal cancer [79,80], malig-
nant mesothelioma [81] and multiple myeloma [82] and
a high metastatic potential in hepatocellular and
colorectal carcinomas [83-86]. Downregulation of synde-
can-2 and -4 expression has also been observed in certain
human carcinomas [78,87-89], but the functional conse-
quences of these alterations in expression are less clear.
In contrast to the general notion that the syndecan may be
an inhibitor of carcinogenesis, syndecan-1 also demon-
strates tumor promoter function. Syndecan-1 supple-
ments Wnt-1 induced tumorigenesis of the mouse
mammary gland [90] and promotes the formation of
metastases in mouse lung squamous carcinoma cells [75].
Enhanced syndecan-1 expression has also been observed
in pancreatic [91], gastric [92] and breast [93-95] carcino-
mas and this overexpression correlates with increased
tumor aggressiveness and poor clinical prognosis. This
duality in the role of syndecan-1 in tumorigenesis may
reflect tissue and/or tumor stage-specific function, or
reflect the multiple functions of this PG.
Sanderson was the first to demonstrate a role for synde-
can-1 in tumor cell migration by examining the invasion
of myeloma cells into collagen gels [96]. Ectopic expres-
sion of syndecan-1 in syndecan-deficient myeloma cells
had the striking effect of curtailing invasion, whereas the
expression of other cell surface heparan sulfate PGs (e.g.,
glypican) was without effect. Using chimeras derived from
these two proteins, Sanderson showed that the activity of
the syndecan is preserved when its ectodomain alone is
expressed as a glycosyl-phosphatidylinositol (GPI)-linked
protein at the cell surface. Although clearly responsible for
binding the collagen matrix via its attached heparan sul-
fate chains, the anti-invasive activity of the syndecan
requires yet an additional interaction that traces to a site
in the extracellular domain of the core protein itself. The
mechanism by which the ectodomain site influences the
invasion of the myeloma cells is unknown, but its interac-
tion with other cell surface receptors in a "co-receptor"
role is one possibility. More recently, ectopic expression of
syndecan-1 has also been shown to curtail the invasion of
hepatocellular carcinoma cells into a collagen matrix [97].
In a recent study examining syndecan-1 in epithelial cells,
we have shown a critical role for syndecan-1 in αvβ3
integrin signaling activity (Figure 3) [98]. Most mammary
carcinoma cells express multiple syndecan family mem-
bers (e.g., syndecan-1, syndecan-2, syndecan-4) as well as
other cell surface heparan sulfate PGs (e.g., glypican-1).
Because adhesion via heparan sulfate to matrix ligands is
likely to simultaneously involve all of these receptors, the
use of core protein-specific antibodies is the only reliable
way to study the adhesion-signaling role of a specific syn-
decan. This also allows investigation of the syndecan-Reproductive Biology and Endocrinology 2004, 2 http://www.rbej.com/content/2/1/3
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mediated adhesion without ligand engagement by
integrins that would otherwise also participate in binding
to a matrix ligand. Employing this procedure with MDA-
MB-231 cells, a highly invasive human mammary carci-
noma cell line that endogenously expresses syndecans-1
and -4, demonstrates that the cells strongly adhere to mAb
B-B4 (specific for human syndecan-1) but fail to spread in
response to the syndecan ligation. This result was
Syndecan-1 adhesion-mediated signaling in human mammary carcinomas Figure 3
Syndecan-1 adhesion-mediated signaling in human mammary carcinomas. In response to syndecan-1 ligation, αvβ3 
integrins and syndecan-1 form a signaling complex that regulates cytoskeletal reorganization. Cells initially fail to spread in 
response to syndecan-1 ligation because signaling downstream of this complex is negatively regulated by activated α2β1 
integrins. Treatment of cells with a neutralizing β1 integrin antibody relieves this inhibitory signal allowing cells to initiate a 
spreading response. Intriguingly, signaling occurs in the absence of an integrin ligand suggesting that syndecan-1 participates in 
the allosteric activation of αvβ3 integrins. While activated αvβ3 integrins are required for signaling (i.e. spreading is blocked by 
αvβ3 integrin blocking antibody), molecular interactions of the syndecan-1 core protein are also required as signaling is blocked 
by soluble murine syndecan-1ectodomain (mS1ED). In our model, the syndecan physically associates with the αvβ3 integrin via 
an ectodomain interaction, although a functional coupling via an indirect mechanism has not been ruled out. Further, while our 
data suggest that the syndecan's transmembrane and cytoplasmic domains are not absolutely required for signaling, the possi-
bility that these domains may have important regulatory roles cannot be excluded.Reproductive Biology and Endocrinology 2004, 2 http://www.rbej.com/content/2/1/3
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intriguing for several reasons. First, these cells are mam-
mary epithelial cells – a cell type in which it is known syn-
decan-1 functions to regulate cell morphology [66].
Second, it contrasts with studies with other cell types (e.g.,
Raji, myeloma, COS, etc.) in which adherence via synde-
can-1 leads to an active signaling and spreading process.
Finally, the cells do spread when plated on the HepII
domain of fibronectin, which can engage multiple cell
surface PGs, or in response to syndecan-4 ligation. As
MDA-MB-231 cells adherent via syndecan-4 spread and
cells adherent via syndecan-1 do not, these results indicate
that syndecan-1 and -4 may trigger different signaling
pathways and that the syndecan-1 adhesion-signaling
pathway may be missing or selectively shut-off.
What does it take to turn the syndecan-1 signal on?
Despite their initial failure to spread when adherent via
syndecan-1 alone, MDA-MB-231 cells do spread if treated
with 1 mM manganese (Mn2+). As Mn2+ induces confor-
mational shifts that mimic the physiological activation of
β1 and β3 integrins, these results indicated that it might be
necessary to activate one of the β1 integrins, or the αvβ3
integrin, on these cells as an integrin partner working in
collaboration with syndecan-1 ligation.
The identity of which integrin(s) cooperate with synde-
can-1 was determined using modulatory antibodies to
induce conformational shifts that mimic the active or
inactive states of a particular integrin. These studies
revealed that activation of β1 integrins is not required for
syndecan-1 mediated cell spreading. In fact, inhibition of
β1 integrins induces cell spreading – presumably by releas-
ing the integrins'-dependent suppression of the syndecan.
Use of other integrin modulatory antibodies demon-
strated that syndecan-1 collaborates with the αvβ3 integrin
to initiate a positive spreading signal and that trans-dom-
inant inhibition arising from an α2β1-αvβ3 integrin cross-
talk prevents this signal from being generated. Intrigu-
ingly, cooperative signaling via αvβ3 integrins occurs in
the absence of an integrin ligand (i.e. syndecan-1 ligation
is sufficient) – a contention supported by evidence from
other published works that unligated integrins are capable
of transmitting intracellular signals both in vitro and in
vivo [1-9]. What role, syndecan-1 plays, if any, in the allos-
teric activation of αvβ3 integrins is presently unknown.
However, our current work indicates that ectopic expres-
sion of murine syndecan-1 can block β1 integrin function
in human mammary carcinoma cells (Burbach and Rap-
raeger, in preparation). As such, the failure of MDA-MB-
231 cells to initially spread may trace to sub-optimal
levels of cell surface syndecan-1 expression and as a con-
sequence, hyperactivation of β1 integrins. In fact, MDA-
MB-231 cells overexpressing human or murine syndecan-
1 are capable of spreading in response to syndecan-1 liga-
tion in the absence of β1 integrin blockade (unpublished
work).
An important feature of the syndecan necessary for signal-
ing appears to be its ectodomain. Specific evidence sup-
porting a role for the ectodomains of syndecan-1 and -4 in
cell adhesion has previously been described in our labora-
tory [99,100]. Soluble murine syndecan-1 ectodomain
competitively inhibits MDA-MB-231 cell spreading in a
dose-dependent manner. This competition is specific for
syndecan-1, as soluble syndecan-4 ectodomain fails to
compete. These results suggest that soluble murine synde-
can-1 competes with the endogenous human syndecan
for a critical cell surface interaction required for signaling
during cell spreading. Indeed, expression of a syndecan-1
mutant, in which a portion of the ectodomain is deleted,
fails to signal spreading, while deletion of the syndecan-1
transmembrane and cytoplasmic tail is without effect
(unpublished work). These results indicate a regulatory
role for the syndecan-1 ectodomain in the regulation of
epithelial cell morphology, in agreement with earlier pub-
lished works [67,101].
Syndecan-4 Regulation of β1 Integrin in 
Carcinomas
Upregulation of syndecan-4 has been noted in hepatocel-
lular carcinomas and malignant mesotheliomas
[102,103] and such overexpression may correlate with
increased tumor cell proliferation [104-106]. Addition-
ally, syndecan-4 has been shown to enhance β1 integrin
function. Mesenchymal and epithelial cells when seeded
on an heparan sulfate-specific ligand, the cysteine rich
domain of adisintegrin and metalloprotease, ADAM-12/
Meltrin α (rADAM12-cys), cells will bind and spread in a
manner that requires signaling by both syndecan-4 and β1
integrins [8,9,107]. These results imply that the syndecan
can trigger signaling cascades required for cell spreading
either by exposing a cryptic binding site for β1 integrins, as
has been proposed for fibronectin [108], or by modulat-
ing the activity of β1 integrins. Interestingly, colon carci-
noma cells attach but fail to spread on aADAM12-cys.
However, exogenous stimulation of β1 integrins with 1
mM Mn2+  or  β1  integrin function-activating antibody
induced cell spreading, suggesting that in transformed
cells the ADAM-12-syndecan-4 complex fails to activate β1
integrins. The molecular mechanism required for synde-
can-β1 integrin receptor cross-talk involves, in part, synde-
can-4 dependent activation of PKCα and this activation is
required for cell spreading [9]. Additional effectors
required for cell spreading which are activated down-
stream of the syndecan-integrin signaling complex
include Rac1 and the lipid kinase, phosphoinositide 3-
kinase (PI-3K; Dr. Charles Thodeti, personal communica-
tion); activation of RhoA is required for stress-fiber forma-
tion, but not for cell spreading [9]. ADAM-12 has beenReproductive Biology and Endocrinology 2004, 2 http://www.rbej.com/content/2/1/3
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implicated in the differentiation and fusion of skeletal
myoblasts [109-111] and its expression is dramatically
upregulated in a number of carcinomas [107]. Further, the
cytoplasmic tail of ADAM-12 interacts directly with the
actin cytoskeleton via α-actinin [112,113] and contains
several Src homology 3 (SH3) binding motifs which have
been shown to interact with and stimulate the activity of
Src tyrosine kinase, the adaptor protein growth-factor
receptor-bound protein-2 (Grb-2) and PI-3K [114-116].
These results indicate that ADAM-12-syndecan signaling
complexes may regulate cell adhesion and migration dur-
ing the processes of development and metastasis.
Syndecan-2 Expression Levels Lead to Tumor 
Invasion
Syndecan-2 has been implicated in two emerging cancer
scenarios. One involves a role in fibronectin assembly,
focal adhesion formation and migration in Lewis Lung
carcinoma cell variants. The second is a role in adhesion
and proliferation of syndecan-2 overexpressing colon car-
cinoma cells.
The P29 and LM66-H11 cells are two cell-culture variants
derived from the rat Lewis lung carcinoma. The P29 cells
represent a low metastatic tumor that induces a potent
host-stroma response leading to the accumulation of a
fibronectin-rich stromal matrix in vivo [117,118]. In vitro,
the P29 cells attach to fibronectin and respond to this
matrix ligand by assembling focal adhesions and actin
stress fibers [119,120]. This is reminiscent of focal adhe-
sion assembly typically seen by most cells that employ
fibronectin-binding integrin (usually α5β1) and syndecan-
4, which is responsible for binding PKCα and PIP2 via its
unique cytoplasmic domain. In the P29 carcinoma cells,
however, there is a distinct requirement for syndecan-2,
which is the syndecan family member most closely related
to syndecan-4. This requirement is best illustrated by the
H11 variant that expresses reduced levels of syndecan-2 at
the cell surface compared to the P29 cells [120]. These
cells do not form focal adhesions or stress fibers on
fibronectin. The cytoskeletal morphology of the cells
mimics that observed of the same cells plated on the cell-
binding fragment of fibronectin alone (i.e., assemble
cortical actin in response to α5β1 ligation by the fibronec-
tin), but show little response to the "heparin" – binding
domain of this matrix ligand. Importantly, this failure
takes place despite the expression of syndecan-4. This sug-
gests that syndecan-2 is a critical component in the signal-
ing pathway that relays adhesion to fibronectin into
cytoskeletal assembly. This hypothesis is further sup-
ported by the finding that plating the P29 cells on a sub-
stratum consisting of the cell-binding domain of
fibronectin supplemented with syndecan-2 core protein
antibody leads to focal adhesion and stress fiber forma-
tion, in the apparent absence of syndecan-4 ligation. In
addition, increasing the expression of syndecan-2 in H11
cells restores their ability to assemble focal adhesions on
fibronectin and blocking syndecan-2 expression in the
P29 cells using anti-sense oligonucleotides reverts their
phenotype to that of the H11 cells [119,120].
What does this mean? It seems clear that syndecan-2 and
syndecan-4 can have overlapping roles, even though the
role described for syndecan-4 in binding activated PKCα
in focal adhesion seems unlikely to be duplicated by syn-
decan-2. One unanswered question is what role syndecan-
4 plays in Lewis lung carcinoma cells. Is its participation
in the adhesion-signaling pathway at all required? Per-
haps the syndecan-4 protein is partially activated or inac-
tivated and signaling through syndecan-2 complements
and completes the signal. Alternatively, syndecan-4 may
be relegated to a non-functional state that allows synde-
can-2 to supplant its function. This scenario is reminiscent
of findings from the syndecan-4 null mouse in which syn-
decan-2 may compensate for the loss of syndecan-4 in
fibroblast focal adhesions [121]. What function has been
supplanted? At present, data suggest that syndecan-2 cyto-
plasmic domain does not have the ability to bind PIP2 or
activate PKCα, functions ascribed to syndecan-4 alone.
Thus, other functions of the syndecan core protein and/or
its heparan sulfate chains must be taking place, functions
that may include interactions with the integrin itself, or
modify the integrin adhesions through assembly of the
fibronectin, a role for which syndecan-2 is becoming
known.
Syndecan-2 is often over-expressed by 2–5 fold in colon
carcinoma. This overexpression, which induces to a
rounded adhesion phenotype and piling-up of cells in
culture [87,122], also correlates with an invasive pheno-
type [123]. Reduction in syndecan-2 expression by treat-
ment with trichostatin A, a specific inhibitor of histone
deacetylase, converts the cells from this transformed phe-
notype to flattered monolayers that display an organized
cytoskeleton [87,122]. The transformed cells also display
enhanced cell proliferation and growth in soft agar,
which, interestingly, can be blocked by adding exogenous,
soluble syndecan-2 extracellular domain or by reducing
syndecan-2 expression with anti-sense oligonucleotides
[87]. This causes rounding of the adherent cells, G0/G1 cell
cycle arrest and reduction in epidermal growth factor
(EGF)-stimulated extracellular signal-regulated kinase
(ERK) activation, thus dramatically reducing cell growth
in soft agar. Syndecan-4 ectodomain is without effect.
Intriguingly, ectodomain of syndecan-2 is also without
effect on colon carcinoma cells that do not overexpress
syndecan-2. This suggests that overexpression of synde-
can-2 leads to an altered signaling phenotype that traces
in part to its extracellular protein domain.Reproductive Biology and Endocrinology 2004, 2 http://www.rbej.com/content/2/1/3
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Conclusions and Future Directions
Fundamental to the process of tumor cell metastasis is
dynamic, and often rapid, regulation of cell surface adhe-
sion receptors and commensurate rearrangement of the
actin cytoskeleton. However, the mechanisms by which
tumor cells modulate integrin adhesiveness are not fully
understood. Many ECM ligands contain closely spaced
proteoglycan- and integrin-binding domains, suggesting
that these two types of adhesion receptors function in
concert to stimulate cytoskeletal reorganization, migra-
tion and invasion. The mechanism by which syndecans
can act as co-receptors with integrins remains unknown,
but recent studies point to the syndecan extracellular
protein domains, that appear to complement the binding
interactions of their attached heparan sulfate chains. In
addition, these interactions are likely to supplement activ-
ities of the conserved transmembrane and intracellular
domains, through which syndecan adhesion-mediated
signaling cascades may alter or amplify integrin-mediated
signaling pathways. Understanding the mechanism(s) by
which the syndecans participate in this signaling may lead
to novel therapeutic strategies to control tumor cell inva-
sion and metastasis.
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